{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:17:38Z","timestamp":1793128658053,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS113233"],"award-info":[{"award-number":["NS113233"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ForeBatten Research Foundation, Batten Disease Support and Research Alliance"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1038\/s41591-020-0986-1","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T16:04:39Z","timestamp":1595865879000},"page":"1444-1451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease"],"prefix":"10.1038","volume":"26","author":[{"given":"Jessica L.","family":"Centa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine M.","family":"Jodelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-942X","authenticated-orcid":false,"given":"Tyler B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ochaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik M.","family":"Duelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-9261","authenticated-orcid":false,"given":"Michelle L.","family":"Hastings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"986_CR1","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1091\/mbc.e03-02-0120","volume":"15","author":"A Kyttala","year":"2004","unstructured":"Kyttala, A., Ihrke, G., Vesa, J., Schell, M. J. & Luzio, J. P. Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. Mol. Biol. Cell 15, 1313\u20131323 (2004).","journal-title":"Mol. Biol. Cell"},{"key":"986_CR2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0092-8674(95)90274-0","volume":"82","author":"The International Batten Disease Consortium","year":"1995","unstructured":"The International Batten Disease Consortium Isolation of a novel gene underlying Batten disease, CLN3. Cell 82, 949\u2013957 (1995).","journal-title":"Cell"},{"key":"986_CR3","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.bbadis.2015.04.027","volume":"1852","author":"J C\u00e1rcel-Trullols","year":"2015","unstructured":"C\u00e1rcel-Trullols, J., Kov\u00e1cs, A. D. & Pearce, D. A. Cell biology of the NCL proteins: what they do and don\u2019t do. Biochim. Biophys. Acta 1852, 2242\u20132255 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"986_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10545-011-9421-6","volume":"35","author":"J Cialone","year":"2012","unstructured":"Cialone, J. et al. Females experience a more severe disease course in Batten disease. J. Inherit. Metab. Dis. 35, 549\u2013555 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"986_CR5","first-page":"211","volume":"89","author":"RM Gardiner","year":"2002","unstructured":"Gardiner, R. M. Clinical features and molecular genetic basis of the neuronal ceroid lipofuscinoses. Adv. Neurol. 89, 211\u2013215 (2002).","journal-title":"Adv. Neurol."},{"key":"986_CR6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","volume":"15","author":"TB Johnson","year":"2019","unstructured":"Johnson, T. B. et al. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat. Rev. Neurol. 15, 161\u2013178 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"986_CR7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.gene.2016.08.031","volume":"593","author":"DE Sleat","year":"2016","unstructured":"Sleat, D. E., Gedvilaite, E., Zhang, Y., Lobel, P. & Xing, J. Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis. Gene 593, 284\u2013291 (2016).","journal-title":"Gene"},{"key":"986_CR8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","volume":"1852","author":"SE Mole","year":"2015","unstructured":"Mole, S. E. & Cotman, S. L. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim. Biophys. Acta 1852, 2237\u20132241 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"986_CR9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/humu.21624","volume":"33","author":"M Kousi","year":"2012","unstructured":"Kousi, M., Lehesjoki, A. E. & Mole, S. E. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum. Mutat. 33, 42\u201363 (2012).","journal-title":"Hum. Mutat."},{"key":"986_CR10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00439-013-1381-5","volume":"133","author":"F Wang","year":"2014","unstructured":"Wang, F. et al. Next generation sequencing-based molecular diagnosis of retinitis pigmentosa: identification of a novel genotype-phenotype correlation and clinical refinements. Hum. Genet. 133, 331\u2013345 (2014).","journal-title":"Hum. Genet."},{"key":"986_CR11","doi-asserted-by":"crossref","first-page":"20483","DOI":"10.1074\/jbc.M602180200","volume":"281","author":"Y Cao","year":"2006","unstructured":"Cao, Y. et al. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J. Biol. Chem. 281, 20483\u201320493 (2006).","journal-title":"J. Biol. Chem."},{"key":"986_CR12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1471-4159.2010.07158.x","volume":"116","author":"JW Chang","year":"2011","unstructured":"Chang, J. W., Choi, H., Cotman, S. L. & Jung, Y. K. Lithium rescues the impaired autophagy process in CbCln3(\u0394ex7\/8\/\u0394ex7\/8) cerebellar cells and reduces neuronal vulnerability to cell death via IMPase inhibition. J. Neurochem. 116, 659\u2013668 (2011).","journal-title":"J. Neurochem."},{"key":"986_CR13","doi-asserted-by":"crossref","first-page":"14361","DOI":"10.1074\/jbc.M114.621706","volume":"290","author":"U Chandrachud","year":"2015","unstructured":"Chandrachud, U. et al. Unbiased cell-based screening in a neuronal cell model of Batten disease highlights an interaction between Ca2+ homeostasis, autophagy, and CLN3 protein function. J. Biol. Chem. 290, 14361\u201314380 (2015).","journal-title":"J. Biol. Chem."},{"key":"986_CR14","doi-asserted-by":"crossref","first-page":"e55526","DOI":"10.1371\/journal.pone.0055526","volume":"8","author":"JM Vidal-Donet","year":"2013","unstructured":"Vidal-Donet, J. M., C\u00e1rcel-Trullols, J., Casanova, B., Aguado, C. & Knecht, E. Alterations in ROS activity and lysosomal pH account for distinct patterns of macroautophagy in LINCL and JNCL fibroblasts. PLoS One 8, e55526 (2013).","journal-title":"PLoS One"},{"key":"986_CR15","doi-asserted-by":"crossref","first-page":"jcs234047","DOI":"10.1242\/jcs.234047","volume":"133","author":"S Yasa","year":"2020","unstructured":"Yasa, S. et al. CLN3 regulates endosomal function by modulating Rab7A-effector interactions. J. Cell Sci. 133, jcs234047 (2020).","journal-title":"J. Cell Sci."},{"key":"986_CR16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4161\/auto.4451","volume":"3","author":"S Kimura","year":"2007","unstructured":"Kimura, S., Noda, T. & Yoshimori, T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3, 452\u2013460 (2007).","journal-title":"Autophagy"},{"key":"986_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","volume":"12","author":"DJ Klionsky","year":"2016","unstructured":"Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1\u2013222 (2016).","journal-title":"Autophagy"},{"key":"986_CR18","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","volume":"44","author":"MA Havens","year":"2016","unstructured":"Havens, M. A. & Hastings, M. L. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 44, 6549\u20136563 (2016).","journal-title":"Nucleic Acids Res."},{"key":"986_CR19","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1093\/hmg\/11.22.2709","volume":"11","author":"SL Cotman","year":"2002","unstructured":"Cotman, S. L. et al. Cln3(\u0394ex7\/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum. Mol. Genet. 11, 2709\u20132721 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"986_CR20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1750-3639.2004.tb00077.x","volume":"14","author":"J Tyynela","year":"2004","unstructured":"Tyynela, J., Cooper, J. D., Khan, M. N., Shemilts, S. J. & Haltia, M. Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation. Brain Pathol. 14, 349\u2013357 (2004).","journal-title":"Brain Pathol."},{"key":"986_CR21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1601-183X.2009.00478.x","volume":"8","author":"NS Osorio","year":"2009","unstructured":"Osorio, N. S. et al. Neurodevelopmental delay in the Cln3\u0394ex7\/8 mouse model for Batten disease. Genes Brain Behav. 8, 337\u2013345 (2009).","journal-title":"Genes Brain Behav."},{"key":"986_CR22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.brainres.2004.07.030","volume":"1023","author":"CC Pontikis","year":"2004","unstructured":"Pontikis, C. C. et al. Late onset neurodegeneration in the Cln3\n-\/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res. 1023, 231\u2013242 (2004).","journal-title":"Brain Res."},{"key":"986_CR23","doi-asserted-by":"crossref","first-page":"e95023","DOI":"10.1371\/journal.pone.0095023","volume":"9","author":"M Burkovetskaya","year":"2014","unstructured":"Burkovetskaya, M. et al. Evidence for aberrant astrocyte hemichannel activity in juvenile neuronal ceroid lipofuscinosis (JNCL). PLoS One 9, e95023 (2014).","journal-title":"PLoS One"},{"key":"986_CR24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hum.2012.253","volume":"25","author":"D Sondhi","year":"2014","unstructured":"Sondhi, D. et al. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. Hum. Gene Ther. 25, 223\u2013239 (2014).","journal-title":"Hum. Gene Ther."},{"key":"986_CR25","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ana.24815","volume":"80","author":"A Aldrich","year":"2016","unstructured":"Aldrich, A. et al. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3). Ann. Neurol. 80, 909\u2013923 (2016).","journal-title":"Ann. Neurol."},{"key":"986_CR26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1242\/dmm.018804","volume":"8","author":"AD Kov\u00e1cs","year":"2015","unstructured":"Kov\u00e1cs, A. D. & Pearce, D. A. Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender. Dis. Model Mech. 8, 351\u2013361 (2015).","journal-title":"Dis. Model Mech."},{"key":"986_CR27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1326-9-31","volume":"9","author":"X Wang","year":"2014","unstructured":"Wang, X., Huang, T., Bu, G. & Xu, H. Dysregulation of protein trafficking in neurodegeneration. Mol. Neurodegener. 9, 31 (2014).","journal-title":"Mol. Neurodegener."},{"key":"986_CR28","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1093\/brain\/awu278","volume":"137","author":"DS Yang","year":"2014","unstructured":"Yang, D. S. et al. Defective macroautophagic turnover of brain lipids in the TgCRND8 Alzheimer mouse model: prevention by correcting lysosomal proteolytic deficits. Brain 137, 3300\u20133318 (2014).","journal-title":"Brain"},{"key":"986_CR29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.celrep.2013.08.042","volume":"5","author":"P Nilsson","year":"2013","unstructured":"Nilsson, P. et al. A\u03b2 secretion and plaque formation depend on autophagy. Cell Rep. 5, 61\u201369 (2013).","journal-title":"Cell Rep."},{"key":"986_CR30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/0304-3940(90)90176-A","volume":"120","author":"KE Wisniewski","year":"1990","unstructured":"Wisniewski, K. E., Kida, E., Gordon-Majszak, W. & Saitoh, T. Altered amyloid \u03b2-protein precursor processing in brains of patients with neuronal ceroid lipofuscinosis. Neurosci. Lett. 120, 94\u201396 (1990).","journal-title":"Neurosci. Lett."},{"key":"986_CR31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/BF00710273","volume":"16","author":"KE Wisniewski","year":"1993","unstructured":"Wisniewski, K. E., Gordon-Krajcer, W. & Kida, E. Abnormal processing of carboxy-terminal fragment of beta precursor protein (\u03b2PP) in neuronal ceroid-lipofuscinosis (NCL) cases. J. Inherit. Metab. Dis. 16, 312\u2013316 (1993).","journal-title":"J. Inherit. Metab. Dis."},{"key":"986_CR32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0304-3940(01)02444-2","volume":"323","author":"MR D\u2019Andrea","year":"2002","unstructured":"D\u2019Andrea, M. R. et al. Lipofuscin and A\u03b242 exhibit distinct distribution patterns in normal and Alzheimer\u2019s disease brains. Neurosci. Lett. 323, 45\u201349 (2002).","journal-title":"Neurosci. Lett."},{"key":"986_CR33","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1093\/hmg\/dds322","volume":"21","author":"M Maulik","year":"2012","unstructured":"Maulik, M. et al. Mutant human APP exacerbates pathology in a mouse model of NPC and its reversal by a \u03b2-cyclodextrin. Hum. Mol. Genet. 21, 4857\u20134875 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"986_CR34","doi-asserted-by":"crossref","first-page":"21562","DOI":"10.1074\/jbc.M100710200","volume":"276","author":"MA Chishti","year":"2001","unstructured":"Chishti, M. A. et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21562\u201321570 (2001).","journal-title":"J. Biol. Chem."},{"key":"986_CR35","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","volume":"33","author":"BT Darras","year":"2019","unstructured":"Darras, B. T. et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with Nnusinersen in seven clinical trials. CNS Drugs 33, 919\u2013932 (2019).","journal-title":"CNS Drugs"},{"key":"986_CR36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coph.2015.07.005","volume":"24","author":"G McClorey","year":"2015","unstructured":"McClorey, G. & Wood, M. J. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr. Opin. Pharm. 24, 52\u201358 (2015).","journal-title":"Curr. Opin. Pharm."},{"key":"986_CR37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"KD Foust","year":"2010","unstructured":"Foust, K. D. et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28, 271\u2013274 (2010).","journal-title":"Nat. Biotechnol."},{"key":"986_CR38","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","volume":"15","author":"T Dangouloff","year":"2019","unstructured":"Dangouloff, T. & Servais, L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther. Clin. Risk Manag. 15, 1153\u20131161 (2019).","journal-title":"Ther. Clin. Risk Manag"},{"key":"986_CR39","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo, D. C. et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul. Disord. 29, 842\u2013856 (2019).","journal-title":"Neuromuscul. Disord."},{"key":"986_CR40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12519-019-00242-6","volume":"15","author":"Q Ke","year":"2019","unstructured":"Ke, Q. et al. Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy. World J. Pediatr. 15, 219\u2013225 (2019).","journal-title":"World J. Pediatr."},{"key":"986_CR41","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/bioinformatics\/btn221","volume":"24","author":"H Viklund","year":"2008","unstructured":"Viklund, H. & Elofsson, A. OCTOPUS: improving topology prediction by two-track ANN-based preference scores and an extended topological grammar. Bioinformatics 24, 1662\u20131668 (2008).","journal-title":"Bioinformatics"},{"key":"986_CR42","doi-asserted-by":"crossref","first-page":"e1000213","DOI":"10.1371\/journal.pcbi.1000213","volume":"4","author":"SM Reynolds","year":"2008","unstructured":"Reynolds, S. M., Kall, L., Riffle, M. E., Bilmes, J. A. & Noble, W. S. Transmembrane topology and signal peptide prediction using dynamic bayesian networks. PLoS Comput. Biol. 4, e1000213 (2008).","journal-title":"PLoS Comput. Biol."},{"key":"986_CR43","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jmb.2004.03.016","volume":"338","author":"L Kall","year":"2004","unstructured":"Kall, L., Krogh, A. & Sonnhammer, E. L. A combined transmembrane topology and signal peptide prediction method. J. Mol. Biol. 338, 1027\u20131036 (2004).","journal-title":"J. Mol. Biol."},{"key":"986_CR44","doi-asserted-by":"crossref","first-page":"i251","DOI":"10.1093\/bioinformatics\/bti1014","volume":"21","author":"L Kall","year":"2005","unstructured":"Kall, L., Krogh, A. & Sonnhammer, E. L. An HMM posterior decoder for sequence feature prediction that includes homology information. Bioinformatics 21, i251\u2013i257 (2005).","journal-title":"Bioinformatics"},{"key":"986_CR45","doi-asserted-by":"crossref","first-page":"7177","DOI":"10.1073\/pnas.0711151105","volume":"105","author":"A Bernsel","year":"2008","unstructured":"Bernsel, A. et al. Prediction of membrane-protein topology from first principles. Proc. Natl Acad. Sci. USA 105, 7177\u20137181 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"986_CR46","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1093\/bioinformatics\/btn550","volume":"24","author":"H Viklund","year":"2008","unstructured":"Viklund, H., Bernsel, A., Skwark, M. & Elofsson, A. SPOCTOPUS: a combined predictor of signal peptides and membrane protein topology. Bioinformatics 24, 2928\u20132929 (2008).","journal-title":"Bioinformatics"},{"key":"986_CR47","doi-asserted-by":"crossref","first-page":"W401","DOI":"10.1093\/nar\/gkv485","volume":"43","author":"KD Tsirigos","year":"2015","unstructured":"Tsirigos, K. D., Peters, C., Shu, N., Kall, L. & Elofsson, A. The TOPCONS web server for consensus prediction of membrane protein topology and signal peptides. Nucleic Acids Res. 43, W401\u2013W407 (2015).","journal-title":"Nucleic Acids Res."},{"key":"986_CR48","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.febslet.2008.02.049","volume":"582","author":"T Nugent","year":"2008","unstructured":"Nugent, T., Mole, S. E. & Jones, D. T. The transmembrane topology of Batten disease protein CLN3 determined by consensus computational prediction constrained by experimental data. FEBS Lett. 582, 1019\u20131024 (2008).","journal-title":"FEBS Lett."},{"key":"986_CR49","doi-asserted-by":"crossref","first-page":"170142","DOI":"10.1098\/rsob.170142","volume":"7","author":"E Perland","year":"2017","unstructured":"Perland, E. et al. Characteristics of 29 novel atypical solute carriers of major facilitator superfamily type: evolutionary conservation, predicted structure and neuronal co-expression. Open Biol. 7, 170142 (2017).","journal-title":"Open Biol."},{"key":"986_CR50","doi-asserted-by":"crossref","first-page":"W174","DOI":"10.1093\/nar\/gkv342","volume":"43","author":"J Yang","year":"2015","unstructured":"Yang, J. & Zhang, Y. I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res. 43, W174\u2013W181 (2015).","journal-title":"Nucleic Acids Res."},{"key":"986_CR51","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nprot.2010.5","volume":"5","author":"A Roy","year":"2010","unstructured":"Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725\u2013738 (2010).","journal-title":"Nat. Protoc."},{"key":"986_CR52","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/bioinformatics\/btt607","volume":"30","author":"U Omasits","year":"2014","unstructured":"Omasits, U., Ahrens, C. H., Muller, S. & Wollscheid, B. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics 30, 884\u2013886 (2014).","journal-title":"Bioinformatics"},{"key":"986_CR53","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","volume":"70","author":"CM Chresta","year":"2010","unstructured":"Chresta, C. M. et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288\u2013298 (2010).","journal-title":"Cancer Res."},{"key":"986_CR54","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","volume":"35","author":"EE Swayze","year":"2007","unstructured":"Swayze, E. E. et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687\u2013700 (2007).","journal-title":"Nucleic Acids Res."},{"key":"986_CR55","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","volume":"350","author":"F Rigo","year":"2014","unstructured":"Rigo, F. et al. Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J. Pharm. Exp. Ther. 350, 46\u201355 (2014).","journal-title":"J. Pharm. Exp. Ther."},{"key":"986_CR56","doi-asserted-by":"crossref","first-page":"11994","DOI":"10.1074\/jbc.272.18.11994","volume":"272","author":"BF Baker","year":"1997","unstructured":"Baker, B. F. et al. 2\u2032-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272, 11994\u201312000 (1997).","journal-title":"J. Biol. Chem."},{"key":"986_CR57","doi-asserted-by":"crossref","first-page":"328","DOI":"10.15252\/emmm.201505846","volume":"8","author":"AJ Hinrich","year":"2016","unstructured":"Hinrich, A. J. et al. Therapeutic correction of ApoER2 splicing in Alzheimer\u2019s disease mice using antisense oligonucleotides. EMBO Mol. Med. 8, 328\u2013345 (2016).","journal-title":"EMBO Mol. Med."},{"key":"986_CR58","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-61779-767-5_20","volume":"867","author":"Y Hua","year":"2012","unstructured":"Hua, Y. & Krainer, A. R. Antisense-mediated exon inclusion. Methods Mol. Biol. 867, 307\u2013323 (2012).","journal-title":"Methods Mol. Biol."},{"key":"986_CR59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.neuropharm.2010.10.010","volume":"60","author":"AD Kov\u00e1cs","year":"2011","unstructured":"Kov\u00e1cs, A. D. et al. Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease. Neuropharmacology 60, 405\u2013409 (2011).","journal-title":"Neuropharmacology"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0986-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0986-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0986-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:03:49Z","timestamp":1684620229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-0986-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["986"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-0986-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"2 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.O, M.J. and F.R. are employees of Ionis Pharmaceuticals. T.B.J. and J.M.W. are currently employees of Amicus Therapeutics. D.M.D. is currently employed by Abbott Molecular. M.L.H. and F.R. are inventors on patents on ASOs filed by RFUMS and Ionis Pharmaceuticals and may be entitled to benefits from licensing of the associated intellectual property.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}